Yes, Wegovy is a GLP-1 receptor agonist. Its active ingredient, semaglutide, mimics a natural hormone called GLP-1 (glucagon-like peptide-1) that your body already produces to regulate appetite and blood sugar. Wegovy is the brand name specifically approved for weight management, while the same molecule is sold under the name Ozempic for type 2 diabetes.
How GLP-1 Drugs Work
Your gut naturally releases GLP-1 after you eat. The hormone signals your brain to reduce hunger, tells your pancreas to release insulin, and slows the rate at which food leaves your stomach. The problem is that natural GLP-1 breaks down in minutes. Semaglutide is engineered to last much longer in the body, which is why Wegovy is injected just once a week rather than continuously.
GLP-1 receptor agonists like Wegovy work on two fronts. In the brain, they act on regions that control appetite and energy balance, reducing the drive to eat. In the rest of the body, they improve blood sugar control by boosting insulin release, suppressing a hormone called glucagon that raises blood sugar, and slowing digestion so glucose enters your bloodstream more gradually. That combination of reduced appetite and improved metabolism is what makes this drug class effective for both weight loss and diabetes management.
What Wegovy Is Approved For
The FDA has approved Wegovy for several specific uses. For weight management, it’s indicated for adults with obesity (a BMI of 30 or higher) or adults with overweight (BMI 27 to 29.9) who also have at least one weight-related condition like high blood pressure or high cholesterol. It’s also approved for children aged 12 and older whose BMI falls at or above the 95th percentile for their age and sex.
Beyond weight loss, Wegovy is approved to reduce the risk of serious cardiovascular events in adults with obesity or overweight who already have heart or blood vessel disease. More recently, it gained approval for treating a form of fatty liver disease called MASH in adults with moderate to advanced liver scarring.
How Wegovy Differs From Ozempic
Wegovy and Ozempic contain the exact same molecule, semaglutide, but they’re approved for different purposes and prescribed at different doses. Ozempic is approved for managing blood sugar in type 2 diabetes, with a typical maintenance dose of 1 mg per week and a maximum of 2 mg. Wegovy, designed for weight management, goes higher: the standard maintenance dose is 2.4 mg per week, though some patients stay at 1.7 mg.
Some doctors prescribe Ozempic off-label for weight loss, but Wegovy is the version specifically studied and approved for that purpose at higher doses.
The Dosing Schedule
You don’t start at the full dose. Wegovy follows a gradual 16-week ramp-up designed to let your body adjust and minimize side effects, particularly nausea. The schedule looks like this:
- Weeks 1 through 4: 0.25 mg once weekly
- Weeks 5 through 8: 0.5 mg once weekly
- Weeks 9 through 12: 1 mg once weekly
- Weeks 13 through 16: 1.7 mg once weekly
- Week 17 onward: 1.7 mg or 2.4 mg once weekly (maintenance)
If a particular dose increase causes too many side effects, your prescriber may delay the next step by four weeks to give your body more time to adjust.
Common Side Effects
Digestive issues are the most frequent side effects. Nausea, diarrhea, vomiting, constipation, and abdominal pain all occur in more than 5% of people taking Wegovy. Other common reactions include headache, fatigue, dizziness, acid reflux, bloating, gas, and hair loss.
Most of these side effects are worst during the dose escalation phase and tend to improve as your body adjusts. Still, about 4.3% of patients in clinical trials stopped treatment because of gastrointestinal problems, compared to just 0.7% on placebo. Nausea was the leading reason people quit, followed by vomiting and diarrhea. In adolescent patients aged 12 and older, gastrointestinal side effects were reported in 62% of those taking Wegovy versus 42% on placebo.
Who Should Not Take Wegovy
Wegovy carries an FDA boxed warning related to thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors at doses similar to those used in humans. Whether this risk applies to people remains unknown, but as a precaution, Wegovy is contraindicated if you or a close family member has a history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), which raises the risk of thyroid tumors.